Veness Adam M
Insider CIK 1778623 · XLRN VP, General Counsel and Sec. · CYT General Counsel · DNTH SVP, General Counsel and Sec.
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-13 | 2026-08-14 | 15,000 | — | $0 | 73,240 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-13 | 2026-08-14 | 15,000 | $18.17 | $272.6K | 15,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-13 | 2026-08-14 | 15,000 | — | $0 | 73,240 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-13 | 2026-08-14 | 15,000 | $18.17 | $272.6K | 15,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-10 | 2026-08-11 | 16,167 | — | $0 | 60,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-10 | 2026-08-11 | 16,167 | $110.38 | $1.78M | 0 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-10 | 2026-08-11 | 16,167 | $17.88 | $289.1K | 16,167 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-10 | 2026-08-11 | 16,167 | — | $0 | 60,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-10 | 2026-08-11 | 16,167 | $110.38 | $1.78M | 0 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-10 | 2026-08-11 | 16,167 | $17.88 | $289.1K | 16,167 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-07 | 2026-08-11 | 3,833 | — | $0 | 76,167 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-07 | 2026-08-11 | 3,833 | $17.88 | $68.5K | 3,833 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-07 | 2026-08-11 | 3,217 | $110.61 | $355.8K | 616 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-07 | 2026-08-11 | 616 | $111.18 | $68.5K | 0 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-08-07 | 2026-08-11 | 3,833 | — | $0 | 76,167 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-07 | 2026-08-11 | 616 | $111.18 | $68.5K | 0 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-08-07 | 2026-08-11 | 3,217 | $110.61 | $355.8K | 616 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-08-07 | 2026-08-11 | 3,833 | $17.88 | $68.5K | 3,833 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise deriv | 2026-06-17 | 2026-06-18 | 30,000 | — | $0 | 80,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-06-17 | 2026-06-18 | 16,771 | $80.34 | $1.35M | 13,229 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | M Exercise | 2026-06-17 | 2026-06-18 | 30,000 | $17.88 | $536.4K | 30,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | S Sale | 2026-06-17 | 2026-06-18 | 13,229 | $81.38 | $1.08M | 0 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2026-02-03 | 2026-02-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2025-02-03 | 2025-02-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2024-05-23 | 2024-05-28 | 75,000 | — | $0 | 75,000 | SEC↗ |
| DNTH Dianthus Therapeutics, Inc | A Award deriv | 2024-01-24 | 2024-01-26 | 110,000 | — | $0 | 110,000 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | A Award deriv | 2023-02-03 | 2023-02-07 | 96,100 | — | $0 | 96,100 | SEC↗ |
| CYT Cyteir Therapeutics, Inc. | A Award deriv | 2022-05-02 | 2022-05-04 | 177,000 | — | $0 | 177,000 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 7,650 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 6,700 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 8,500 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 24,334 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | D To issuer deriv | 2021-11-19 | 2021-11-22 | 18,806 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | U Tender | 2021-11-19 | 2021-11-22 | 23,423 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise deriv | 2021-11-09 | 2021-11-12 | 4,500 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise | 2021-11-09 | 2021-11-12 | 4,500 | $29.37 | $132.2K | 23,423 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise deriv | 2021-09-21 | 2021-09-22 | 5,200 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise deriv | 2021-09-21 | 2021-09-22 | 1,450 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-09-21 | 2021-09-22 | 6,650 | $150.05 | $997.8K | 18,923 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise | 2021-09-21 | 2021-09-22 | 1,450 | $41.20 | $59.7K | 25,573 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise | 2021-09-21 | 2021-09-22 | 5,200 | $30.17 | $156.9K | 24,123 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-09-09 | 2021-09-09 | 1,407 | $130.00 | $182.9K | 18,923 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-09-08 | 2021-09-09 | 6 | $130.00 | $780 | 20,330 | SEC↗ |
| XLRN ACCELERON PHARMA INC | F Tax w/h | 2021-09-07 | 2021-09-09 | 587 | $129.36 | $75.9K | 20,336 | SEC↗ |
| XLRN ACCELERON PHARMA INC | F Tax w/h | 2021-06-07 | 2021-06-08 | 108 | $126.69 | $13.7K | 20,923 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2021-01-29 | 2021-02-02 | 18,806 | — | $0 | 18,806 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award | 2021-01-29 | 2021-02-02 | 4,868 | — | $0 | 21,031 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-01-05 | 2021-01-06 | 100 | $124.30 | $12.4K | 16,163 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-01-05 | 2021-01-06 | 1,900 | $122.46 | $232.7K | 16,319 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2021-01-05 | 2021-01-06 | 56 | $122.93 | $6.9K | 16,263 | SEC↗ |
| XLRN ACCELERON PHARMA INC | F Tax w/h | 2021-01-04 | 2021-01-06 | 942 | $124.31 | $117.1K | 18,219 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-09-08 | 2020-09-09 | 1,071 | $89.20 | $95.5K | 20,090 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-09-08 | 2020-09-09 | 929 | $89.85 | $83.5K | 19,161 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise deriv | 2020-04-08 | 2020-04-10 | 6,000 | — | $0 | 0 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-04-08 | 2020-04-10 | 417 | $87.53 | $36.5K | 21,161 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise | 2020-04-08 | 2020-04-10 | 6,000 | $27.97 | $167.8K | 27,161 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-04-08 | 2020-04-10 | 900 | $83.49 | $75.1K | 26,261 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-04-08 | 2020-04-10 | 700 | $84.62 | $59.2K | 25,561 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-04-08 | 2020-04-10 | 2,883 | $85.77 | $247.3K | 22,678 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-04-08 | 2020-04-10 | 1,100 | $86.69 | $95.4K | 21,578 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2020-01-22 | 2020-01-24 | 24,334 | — | $0 | 24,334 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award | 2020-01-22 | 2020-01-24 | 6,369 | — | $0 | 21,161 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-01-03 | 2020-01-03 | 875 | $51.23 | $44.8K | 14,792 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2020-01-02 | 2020-01-03 | 434 | $52.83 | $22.9K | 15,667 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2019-09-10 | 2019-09-10 | 23 | $45.75 | $1.1K | 16,101 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2019-09-10 | 2019-09-10 | 801 | $45.18 | $36.2K | 16,124 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2019-08-09 | 2019-08-12 | 3,268 | $45.00 | $147.1K | 16,925 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2019-07-16 | 2019-07-17 | 538 | $40.71 | $21.9K | 20,193 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2019-06-05 | 2019-06-07 | 6,700 | — | $0 | 6,700 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award | 2019-06-05 | 2019-06-07 | 1,100 | — | $0 | 20,731 | SEC↗ |